LEXINGTON, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, today announced that it will present at the Cowen & Company 34th Annual Health Care Conference at 12:00 noon ET on Monday, March 3, 2014, at the Boston Marriott Copley Place in Boston, MA. Martin Tolar, MD, PhD, Founder, President and CEO of Alzheon, will present at the conference to provide an overview of Alzheon’s drug development pipeline in Alzheimer’s disease, including ALZ-801, the company’s lead clinical candidate starting confirmatory pivotal Phase 2/3 study in early 2015 in Alzheimer’s disease patients positive for ε4 allele of the apolipoprotein E. The presentation will be available on Alzheon’s website www.alzheon.com, under Press Releases.
Alzheon, Inc., is a clinical-stage biotechnology company focused on brain health, memory and aging, developing innovative treatments for Alzheimer’s disease and other neurodegenerative disorders. Alzheon pursues drug development programs with an established safety profile that have previously been tested in extensive efficacy studies in Alzheimer’s disease patients, and where new insights into a disease or molecule can be applied. Based on a drug development platform that yields diverse and novel compounds, the company is building a pipeline of innovative drugs to target the underlying pathogenesis of neurodegeneration in order to improve the symptoms and slow the progression of these devastating diseases. Our lead product candidate, ALZ-801, is a first-in-class small molecule inhibitor of amyloid aggregation and neurotoxicity, and is advancing into a confirmatory pivotal Phase 2/3 study for certain patient populations with Alzheimer’s disease or at risk for the disease. Alzheon has world-leading capabilities in drug development for Alzheimer’s disease and related disorders, and we apply state-of-the-art clinical development approaches to improve the likelihood of success with product candidates in our pipeline, as well as additional therapeutic assets from in-licensing. Alzheon is located in Lexington, Massachusetts, USA. For more information, please visit www.alzheon.com.